News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,336 Results
Type
Article (42485)
Company Profile (294)
Press Release (675557)
Multimedia
Podcasts (79)
Webinars (12)
Section
Business (210445)
Career Advice (2091)
Deals (36630)
Drug Delivery (107)
Drug Development (83059)
Employer Resources (175)
FDA (16575)
Job Trends (15409)
News (356058)
Policy (33921)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (89)
Alliances (51432)
ALS (92)
Alzheimer's disease (1396)
Antibody-drug conjugate (ADC) (132)
Approvals (16580)
Artificial intelligence (266)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (188)
Bladder cancer (77)
Brain cancer (29)
Breast cancer (281)
Cancer (2287)
Cardiovascular disease (182)
Career advice (1751)
Career pathing (31)
CAR-T (152)
Cell therapy (427)
Cervical cancer (19)
Clinical research (67525)
Collaboration (855)
Compensation (530)
Complete response letters (25)
COVID-19 (2660)
CRISPR (45)
C-suite (248)
Cystic fibrosis (103)
Data (2209)
Decentralized trials (2)
Denatured (28)
Depression (45)
Diabetes (272)
Diagnostics (6452)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (111)
Drug shortages (28)
Duchenne muscular dystrophy (94)
Earnings (88262)
Editorial (38)
Employer branding (21)
Employer resources (149)
Events (115217)
Executive appointments (734)
FDA (17837)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (757)
Gene editing (110)
Generative AI (21)
Gene therapy (316)
GLP-1 (745)
Government (4537)
Grass and pollen (5)
Guidances (55)
Healthcare (18998)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (124)
Indications (30)
Infectious disease (2803)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (322)
IPO (16785)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (10)
Labor market (38)
Layoffs (488)
Leadership (17)
Legal (8379)
Liver cancer (76)
Lung cancer (322)
Lymphoma (155)
Machine learning (7)
Management (59)
Manufacturing (317)
MASH (68)
Medical device (13459)
Medtech (13464)
Mergers & acquisitions (20383)
Metabolic disorders (702)
Multiple sclerosis (79)
NASH (17)
Neurodegenerative disease (93)
Neuropsychiatric disorders (29)
Neuroscience (1949)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Northern California (2675)
Now hiring (39)
Obesity (376)
Opinion (229)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (237)
Patient recruitment (109)
Peanut (49)
People (59270)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20942)
Phase II (29709)
Phase III (22265)
Pipeline (1191)
Policy (150)
Postmarket research (2654)
Preclinical (8921)
Press Release (68)
Prostate cancer (107)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (396)
Real estate (6258)
Recruiting (67)
Regulatory (23133)
Reports (46)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (55)
Southern California (2297)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3725)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (41)
The Weekly (49)
United States (23178)
Vaccines (704)
Venture capitalists (41)
Weight loss (250)
Women's health (35)
Worklife (15)
Date
Today (157)
Last 7 days (862)
Last 30 days (2715)
Last 365 days (33412)
2025 (10668)
2024 (35770)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (53)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (40720)
Australia (6521)
California (6114)
Canada (2016)
China (536)
Colorado (268)
Connecticut (273)
Delaware (149)
Europe (86934)
Florida (908)
Georgia (204)
Idaho (57)
Illinois (542)
India (26)
Indiana (315)
Iowa (11)
Japan (163)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (895)
Massachusetts (4598)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1730)
New Mexico (29)
New York (1739)
North Carolina (982)
North Dakota (8)
Northern California (2675)
Ohio (202)
Oklahoma (14)
Oregon (39)
Pennsylvania (1380)
Puerto Rico (12)
Rhode Island (33)
South America (1162)
South Carolina (22)
South Dakota (1)
Southern California (2297)
Tennessee (101)
Texas (909)
Utah (182)
Virginia (152)
Washington D.C. (61)
Washington State (558)
West Virginia (3)
Wisconsin (56)
718,336 Results for "cyclacel pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
April 3, 2025
·
9 min read
Press Releases
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
February 28, 2025
·
10 min read
Business
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024.
May 8, 2024
·
3 min read
Pharm Country
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Cyclacel Pharmaceuticals, Inc. announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor.
June 26, 2024
·
5 min read
Drug Development
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC).
June 4, 2024
·
7 min read
Press Releases
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
January 3, 2025
·
7 min read
Business
Cyclacel Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced first quarter financial results and provided a business update.
May 14, 2024
·
8 min read
Business
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.
March 13, 2024
·
3 min read
Business
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
March 19, 2024
·
9 min read
Pharm Country
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
Cyclacel Pharmaceuticals, Inc. announced that it received £2.3 million as a research & development tax credit from HMRC, the tax agency of the United Kingdom government.
March 6, 2024
·
1 min read
1 of 71,834
Next
